Innovative Technology Platforms

​​​PyroCells Personalized Cancer Vaccine Platform

Pyrojas is revolutionizing personalized cancer immunotherapy with its PyroCells platform, a rapid-response, autologous cancer vaccine technology. PyroCells are designed to address the complex heterogeneity of tumors and neutralize immunosuppressive environments, which are common obstacles in current cancer treatments.

• Antigen-Agnostic Approach: PyroCells target the full repertoire of tumor antigens, promoting a diversified immune response that combats cancer escape mechanisms.

• Rapid Manufacturing: A breakthrough automated system allows point-of-care production of personalized vaccines within 24 hours at the site of surgery, ensuring swift, patient-specific therapies.

• Validated Preclinical Success: Preclinical trials have demonstrated 100% tumor protection, positioning PyroCells as a potentially transformative solution in the fight against cancer.

PyroTIMER T Cell Enhancement Platform

The PyroTIMER platform is designed to supercharge the efficacy of CAR-T and TCR-T cell therapies by overcoming the immunosuppressive tumor immune microenvironment. PyroTIMER significantly enhances T cell persistence, cytotoxicity, and delays exhaustion, allowing these therapies to be more effective in both solid tumors and refractory cancers.

• Modular Technology: PyroTIMER molecules are adaptable, allowing for customized applications across different tumor types and immunotherapy platforms.

• Universal Application: Validated with FDA-approved CAR-T therapies, PyroTIMER can be integrated with existing CAR/TCR technologies globally to enhance clinical outcomes.

• Licensing Opportunities: This platform is licenseable by CAR/TCR-T cell therapy companies worldwide, enabling broad industry adoption of this powerful enhancement platform.